Take of rhesus-human reassortant tetravalent rotavirus vaccine in breast-fed infants.
Rhesus-human reassortant tetravalent rotavirus vaccine at a titer of 4 x 10(4) plaque forming units was evaluated for immunogenicity in 194 6-8-week-old breast-fed Turkish infants. The vaccine was administered orally as a single dose following either a meal of breast milk or 30 ml of sodium bicarbonate-buffered soy milk formula. Four-fold or greater responses in rotavirus IgA ELISA antibody were detected in 62% and 65% of the infants in the two groups, respectively (p = 0.62). In a smaller comparison group of non-breast-fed infants, an IgA response was detected in 7 of 11 (64%) cases. In all vaccinees, a serological response was detected in 72% of the initially seronegative and 47% of the initially seropositive infants (p = 0.001). We conclude that the take of rhesus-human reassortant tetravalent rotavirus vaccine in breast-fed infants is not compromised by breast feeding before vaccination. However, a higher titered preparation of the same vaccine may be required to improve overall immunogenicity in young infants, particularly in those with pre-vaccination rotavirus antibody.
Ceyhan
M
M
Department of Pediatric Infectious Diseases, Hacettepe University Medical School, Ankara, Turkey.
Kanra
G
G
Seçmeer
G
G
Midthun
K
K
Davidson
B L
BL
Zito
E T
ET
Vesikari
T
T
D000284:Administration, Oral; D001942:Breast Feeding; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood / Q000187:drug effects / Q000276:immunology*; D007223:Infant; D007225:Infant Food; D012401:Rotavirus / Q000276:immunology*; D014611:Vaccination; D014613:Vaccines, Attenuated; D014765:Viral Vaccines / Q000008:administration & dosage* / Q000737:chemistry
D007070:Immunoglobulin A; D014613:Vaccines, Attenuated; D014765:Viral Vaccines